(Press-News.org) Rice University chemist and director of the university’s Synthesis X Center Han Xiao and cancer biologist Dihua Yu of The University of Texas MD Anderson Cancer Center have received a three-year, $1.5 million grant from the Robert J. Kleberg Jr. and Helen C. Kleberg Foundation, allowing them to do further research on overcoming the blood-brain barrier (BBB) for the treatment of brain metastasis. This hurdle blocks most cancer therapies from reaching the brain, but the scientists’ innovative approach could transform the treatment of brain metastasis.
The Kleberg Foundation, founded in 1950, seeks groundbreaking medical research proposals from leading institutions, focusing on innovative basic and applied biological research that advances scientific knowledge and human health, according to the organization’s website. Proposals should be novel, challenge existing paradigms and drive progress in the field.
Brain metastasis, the leading form of brain cancer, impacts tens of thousands of patients annually, commonly originating from breast, lung and melanoma cancers. With survival rates plummeting below 20% within a year of diagnosis according to the National Library of Medicine, brain metastasis remains one of the deadliest and most intractable challenges in oncology. The collaboration between SynthX and Yu’s research team aims to rewrite that narrative.
“This collaboration builds on the strengths of both research teams,” Xiao said. “By combining SynthX Center's expertise in chemistry with Dr. Yu's expertise in cancer biology and brain metastases, we aim to create a transformative solution.”
Breaking through the blood-brain barrier
The BBB, a vital defense mechanism that shields the brain from harmful substances, poses a significant challenge in treating brain tumors. This barrier prevents most drugs from reaching the brain with fewer than 2% of Food and Drug Administration-approved small molecule drugs and only a limited number of biological therapies able to cross it. As a result, patients face limited treatment options. While existing therapies like radiotherapy, surgery and systemic treatments such as chemotherapy are available, their effectiveness is often restricted by the BBB’s impermeability.
The inability of most drugs to cross the BBB leads to insufficient drug accumulation at tumor sites, hampering their efficacy, and no widely effective solutions have been developed to date.
Xiao and Yu’s approach involves a cutting-edge light-induced brain delivery (LIBD) platform to address this issue. The advanced system employs nanoparticles embedded with a near-infrared dye to facilitate the transport of therapeutic agents across the BBB.
The researchers aim to evaluate the LIBD’s ability to improve the delivery of small-molecule drugs and biological therapies. Many of these therapies have shown potential for reducing cancer growth in laboratory studies but have struggled to succeed in animal models due to limited BBB penetration.
“Our LIBD platform represents a novel strategy for delivering drugs to the brain with precision and efficiency,” Xiao said. “This technology could not only improve outcomes for brain metastasis patients but also pave the way for treating other neurological diseases.”
A broader impact
The potential applications of the LIBD platform extend beyond cancer treatment. Diseases such as Alzheimer’s, Parkinson’s, epilepsy and glioblastoma also include the challenge of crossing the BBB for effective drug delivery. If successful, this research could revolutionize the treatment landscape for these conditions as well.
For now, the focus remains on brain metastasis, which affects up to 20% of breast cancer patients annually, according to the American Society of Clinical Oncology. By enhancing drug delivery and improving survival rates, Xiao and Yu’s work could transform the standard of care for one of the deadliest forms of cancer.
“This research is a testament to the power of collaboration and innovation,” Xiao said. “Together, we’re pushing the boundaries of what’s possible in treating brain metastasis and beyond.”
END
Rice SynthX and MD Anderson team awarded Kleberg medical grant for brain metastasis research
2025-01-28
[Attachments] See images for this press release:
ELSE PRESS RELEASES FROM THIS DATE:
Microbial therapy offers new hope for vitiligo patients
2025-01-28
‘Astonishing’ findings in mice suggest microbial product could restore skin pigmentation
Offers hope for a disease that affects all skin tones, but is more visible and severe in darker skin
Vitiligo affects 0.5% to 2% of the global population
Patients available for interviews upon request
CHICAGO --- A natural compound derived from gut-friendly bacteria significantly slows the progression of vitiligo and may restore pigmentation, reports a new Northwestern University pre-clinical study in mice.
The findings could offer hope to millions affected by the autoimmune ...
Strategic corporate social responsibility can create social, economic value
2025-01-28
UNIVERSITY PARK, Pa. — Strategic corporate social responsibility (CSR) efforts that are directly related to a hospitality company’s core business operations and competencies can help companies create both social and business value, according to researchers in the Penn State School of Hospitality Management.
Led by Penn State Professor of Hospitality Management Seoki Lee, the research team developed a strategic framework to help hospitality companies optimize their CSR activities — like environmental and social initiatives — to obtain greater social and business value. The researchers published their ...
Researchers identify genetic ‘fingerprint’ to predict drug resistance in bacteria
2025-01-28
Antibiotic resistance is a global public health crisis responsible for more than a million deaths annually. By 2050, the World Health Organization estimates it could surpass cancer and heart disease as the leading cause of death as more bacteria develop defenses to the drugs designed to combat them.
Now Tulane University researchers have identified a unique genetic signature in bacteria that can predict their likelihood of developing antibiotic resistance, according to a new study published in Nature Communications. The findings could help researchers more quickly identify precision-based treatments that are more effective ...
Explaining persistent hydrogen in Mars’ atmosphere
2025-01-28
The fact that the cold, dry Mars of today had flowing rivers and lakes several billion years ago has puzzled scientists for decades. Now, Harvard researchers think they have a good explanation for a warmer, wetter ancient Mars.
Building on prior theories describing the Mars of yore as a hot again, cold again place, a team led by researchers at the Harvard John A. Paulson School of Engineering and Applied Sciences (SEAS) have determined the chemical mechanisms by which ancient Mars was able to sustain enough warmth in its early days ...
Journals publish Montana State ecologist’s studies on the effects of prey depletion on populations of large African carnivores
2025-01-28
By Diana Setterberg, MSU News Service
BOZEMAN – Two recently published studies by a Montana State University ecologist reveal new findings about the relationship between population dynamics of two species of large African carnivores and the availability of their prey.
“The studies are related in a lot of ways,” said Scott Creel, lead author of a paper about the effects of prey depletion on endangered African wild dogs that was published this week in the journal Proceedings of the National Academy of Sciences, and co-lead author of another paper about the effects of poaching controls on African lion demographics that was featured ...
Journal explores dementia-related trends in high- and middle-income countries
2025-01-28
Data from nations around the world can be used to develop strategies for dementia prevention, treatment, and care, according to “Multidisciplinary Perspectives on Dementia and Related Population Health Trends,” a new supplemental issue of The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences.
Alzheimer’s disease and Alzheimer’s-disease-related dementias are a set of conditions involving impaired memory and other cognitive processes that interfere with daily functioning. Worldwide, significant increases in the number of older adults living with dementia are ...
Government Chief Scientific Adviser to launch University of Bath’s new Institute for Digital Security and Behavior
2025-01-28
Professor Dame Angela McLean, Government Chief Scientific Adviser, will lead the launch of the University of Bath’s new Institute for Digital Security and Behaviour (IDSB), on Wednesday 29 January, at Bath’s Guildhall, in a keynote speech on Securing the Future.
The Institute marks a new research collaboration, bringing together behavioural and social scientists to address the risks to society posed by digital technology.
Researchers will study the fundamental causes of vulnerability to harm and the factors that can make people, organisations and societies safer and more ...
Antarctic ice sheet faces “death by a thousand cuts”
2025-01-28
Arecent study conducted by University of Florida geologists and geographers has shed new light on the effects of climate change on Antarctic ice shelves. It found that while there has been broad ice shelf loss due to warming temperatures, the frequency and size of major iceberg calving events has not changed significantly.
This study was led by Assistant Professor of Geological Sciences Emma MacKie, Ph.D., and Assistant Professor of Geography Katy Serafin, Ph.D., along with a collaborator at the Colorado School of Mines.
“Our results suggest that the primary threat ...
Massachusetts General Hospital, Matthew Perry Foundation announce Fellowship in Addiction Medicine
2025-01-28
BOSTON, MA— The Matthew Perry Foundation and Massachusetts General Hospital (MGH), a founding member of the Mass General Brigham healthcare system, today announced the establishment of the Matthew Perry Foundation Fellowship in Addiction Medicine for the 2025/2026 academic year. The fellow will join a highly competitive Addiction Medicine fellowship program, which is one of only 105 available in the United States and trains physicians who have completed an accredited residency program to become specialists and leaders in Addiction Medicine. The fellowship focuses on developing clinical expertise, leadership skills, and training ...
Study shows promise for treating core symptom of frontotemporal dementia
2025-01-28
A new study led by Western researchers found frequent treatment with intranasal oxytocin – a hormone in the brain associated with empathy – offers promise for addressing a key symptom among patients with frontotemporal dementia (FTD): Apathy.
It’s a common issue among those with FTD which affects the frontal and temporal lobes of the brain, impacting language, behaviour and decision making. Patients with FTD lose interest in hobbies and passions that previously brought them joy and, most devastatingly, become apathetic ...